{"url_path":"/sec/rnaz/8-k/2026-06-03/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1829635/0001104659-26-069810-index.html","accession_number":"0001104659-26-069810","cik":"0001829635","ticker":"RNAZ","issuer_name":"Transcode Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829635/0001104659-26-069810-index.html","primary_entity_key":"0001829635","primary_entity_name":"Transcode Therapeutics, Inc."},"word_count":408,"has_tables":true,"body_markdown":"**Item 8.01 Other Events.**\n\n \n\nOn June 3, 2026, TransCode Therapeutics, Inc.\n(“TransCode”) issued a press release announcing further results of its Phase 1a dose escalation clinical trial with TTX-MC138.\nA copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.\n\n \n\n**Note Regarding Forward-Looking Statements**\n\n \n\nThis Current Report on Form 8-K contains\n\"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without\nlimitation, statements concerning the timing, conduct and results of TransCode’s Phase 1a and Phase 2a clinical trials, statements\nabout microRNAs and their involvement in cancer, and statements concerning the therapeutic potential of TransCode's TTX-MC138 and other\ntherapeutic candidates. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations\nof future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely\nfrom those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to:\nthe risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's\npreclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials;\nrisks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including\nTransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions;\nrisks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce\nits patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other\ncompanies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with\ngeopolitical events and pandemics. For a discussion of these and other risks and uncertainties, and other important factors, any of which\ncould cause TransCode's actual results to differ from those contained in or implied by the forward-looking statements, see the section\nentitled \"Risk Factors\" in TransCode's Annual Report on Form 10-K for the year ended December 31, 2025, as well as\ndiscussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the U.S. Securities\nand Exchange Commission. Forward-looking statements reflect TransCode’s analysis only on their stated date; TransCode undertakes\nno duty to update this information unless required by law."}